Form 4: Adaptive Biotechnologies COO Sells Shares

Adaptive Biotechnologies Corp's President and COO, Julie Rubinstein, reported multiple sales and exercises of common stock and options under a pre-arranged trading plan.

Summary

• Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (ADPT), engaged in multiple transactions involving the company's common stock and stock options between March 11 and March 13, 2026.
• A total of 179,703 shares of common stock were disposed of, including 122,523 shares sold to cover tax withholding obligations related to RSU vesting at $13.17 per share.
• An additional 57,120 shares were sold under a Rule 10b5-1 trading plan at weighted average prices ranging from $12.63 to $14.08.
• Rubinstein also exercised 44,166 stock options at an exercise price of $6.55 per share, which were fully vested and exercisable.
• Following these transactions, Rubinstein's direct beneficial ownership of common stock decreased from 520,948 shares (after the initial tax-related sale) to 507,934 shares.
• The number of beneficially owned derivative securities (stock options) decreased from 92,271 to 62,827.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal due to the significant net reduction in insider ownership, despite the pre-planned nature and tax-related component of some sales. While not a discretionary sell-off, it still reduces executive alignment.

Positives

• The exercise of stock options at a strike price of $6.55, significantly below the market sale prices (ranging from $12.63 to $14.08), indicates a profitable transaction for the insider.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on November 18, 2025, suggesting pre-planned activity rather than a reaction to recent negative news.

Negatives

• A significant net reduction in the insider's direct beneficial ownership of common stock by 13,014 shares, in addition to the 122,523 shares sold for tax purposes.
• The total sale of 179,703 shares by a key executive could be perceived negatively by investors, even if partially for tax obligations and pre-planned.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider selling, even when pre-planned under a Rule 10b5-1 plan, is often scrutinized by the market. While the 'sell to cover' portion is non-discretionary and common for RSU vesting, the additional sales, though planned, represent a reduction in executive exposure to the company's equity, which can sometimes be interpreted as a lack of strong conviction, especially in the biotechnology sector where executive alignment is key.

Stakeholder Impact

• Shareholders: May interpret the net selling by a key executive as a negative signal, potentially leading to downward pressure on the stock price.
• Employees: No direct impact mentioned, but executive stock sales can sometimes affect morale if perceived negatively.

Key Dates

Recommendation

While the insider sales, particularly the non-discretionary 'sell to cover' and those under a 10b5-1 plan, are not necessarily indicative of a negative outlook, the significant reduction in a key executive's direct equity exposure warrants caution. Without additional company-specific news or financial performance data, a 'hold' recommendation is prudent to observe market reaction and future company developments.

Keywords

Adaptive Biotechnologies, ADPT, Insider Trading, Form 4, Stock Sale, Stock Option Exercise, Julie Rubinstein, Rule 10b5-1 Plan, Executive Compensation, Equity Sales